NCT04713982Active, not recruitingPhase 2/3
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Source: ClinicalTrials.gov · Last updated 5 Aug 2026
Brief summary (registry, in English)
Examine the effects of deutetrabenazine on functional speech and gait impairment
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 6 Jan 2021
- Start date
- 19 Nov 2021
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Vanderbilt University Medical Center
- Diseases
- Huntington's disease
- NCT number
- NCT04713982
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 30
- From 19 Nov 2021 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Inability to swallow study medication
- Current use of VMAT2 inhibitor (tetrabenazine, deutetrabenazine, valbenazine)
- Concurrent participation in any other investigational drug trials
Other illness
- History of suicidal behavior
- Unstable or serious medical or psychiatric illness
- Renal or hepatic impairment
- Severe speech impairment or anarthria
- History of alcohol or substance abuse within the last 12 months
Other
- Severe depression or suicidal ideation
- Women who are pregnant or breast feeding
- EKG QTcF\> 500 mse
Who the study is looking for
- Diagnosis of HD with documented CAG repeat ≥ 37
- UHDRS total maximal chorea score of ≥ 8
- Able to walk at least 10 meters
- Medically stable outpatient, based on the investigator's judgment
- Willing and able to give written informed consent prior to performing any study procedures
- Have completed at least 10th grade
- Montreal Cognitive Assessment score ≥ 22 on screening
- Female subjects of childbearing potential agree to use an acceptable method of contraception from screening through study completion
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vanderbilt University Medical Center Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.